---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-25-000147"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:39:23.538110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026

## Summary
- Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.
- R&D expenses fell to $27.6M from $48.4M YoY; G&A expenses fell to $8.4M from $16.7M YoY.
- DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC remains on track; topline data expected by year-end 2026.
- Strategic restructuring completed; no further non-recurring expenses expected.
- Part 2 data, if successful, could support accelerated approval subject to FDA feedback.

## SEC filing metadata
- accession: 0001725160-25-000147
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/0001725160-25-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/zntl-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-25-000147
- JSON: https://secwatch.observer/filing/0001725160-25-000147.json
- Plain text: https://secwatch.observer/filing/0001725160-25-000147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.